A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494)Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX

Trial Profile

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494)Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Upadacitinib (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT-MONOTHERAPY
  • Sponsors AbbVie
  • Most Recent Events

    • 02 Feb 2018 Planned End Date changed from 1 Oct 2020 to 20 Oct 2020.
    • 20 Dec 2017 According to an AbbVie media release, Josef S. Smolen is an investigator in the study. Further results of this trial will be presented at a future medical meeting and published in a peer-reviewed publication.
    • 20 Dec 2017 Primary endpoint has been met. (Low Disease Activity (LDA) based on Disease Activity Score (DAS) 28 (CRP)), as reported in an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top